Kintor Pharmaceutical Ltd (HKG: 9939), a biopharmaceutical company based in China, has announced the global launch of cosmetic products featuring pyrilutamide (KX-826) as the key ingredient. Pyrilutamide, an androgen receptor (AR) antagonist, is utilized as a topical application for the treatment of androgenic alopecia (AGA), a common condition leading to hair loss.
The compound has undergone numerous clinical trials for AGA in both male and female subjects in China and the United States, exhibiting excellent safety profiles and significant efficacy in preventing hair loss. Additionally, pyrilutamide is currently in development for the treatment of acne, expanding its potential applications in dermatology.- Flcube.com
